Surgeon says I'm intermediate risk, b... - Advanced Prostate...

Advanced Prostate Cancer

22,286 members27,986 posts

Surgeon says I'm intermediate risk, but I think I'm high risk based on the pathology report below

twostrats profile image
7 Replies

I had an RP in March of this year. The 3 psa tests I've had since then have been <0.1 my question my surgeon calls me intermediate risk, but according to my pathology report with T3a I think I'm high risk.

Final Diagnosis:

1. Periprostatic fat, excision:

- Adipose tissue with no tumor seen.

2. Right peri vesicle bundle margin, excision:

- Fibroconnective tissue and nerves only; no tumor seen.

- Prostatic epithelium is not identified.

3. Prostate and seminal vesicles, prostatectomy:

- Prostatic adenocarcinoma, Gleason's score 7 (4+3) [Grade Group 3].

- The adenocarcinoma invades into thick intersecting smooth muscle bundles

at the right base, consistent with bladder neck

invasion.

- Lymphovascular invasion is not identified.

- Seminal vesicles with no tumor seen.

- Resection margins are negative for carcinoma; adenocarcinoma is less

than 0.001 cm to the right base margin (see part #2).

4. Right pelvic lymph nodes, excision:

- No tumor seen in three lymph nodes (0/3).

5. Left pelvic lymph nodes, excision:

- No tumor seen in six lymph nodes (0/6).

MH/al/mm

Report Name: Prostate - Radical Prostatectomy

Status: Submitted

Part(s) Involved:

3: Prostate and seminal vesicles

Synoptic Report:

Specimen

Procedure: Radical prostatectomy

Tumor

Histologic Type: Acinar adenocarcinoma

Histologic Grade

Grade Group and Gleason Score: Grade group 3 (Gleason Score 4 + 3 =

7)

Percentage of Pattern 4: 65%

Extraprostatic Extension (EPE): Not identified

Urinary Bladder Neck Invasion: Present

Seminal Vesicle Invasion: Not identified

Treatment Effect: No known presurgical therapy

Ma

rgins

Margins: Uninvolved by invasive carcinoma

Lymph Nodes

Number of Lymph Nodes Involved: 0

Number of Lymph Nodes Examined: 9

Pathologic Stage Classification (pTNM, AJCC 8th Edition)

Primary Tumor (pT): pT3a

Regional Lymph Nodes (pN): pN0

CAP eCC February 2020 Annual Release

Gross Description:

Received in five parts

Source of Tissue: 1. Labeled #1, "periprostatic fat"

Gross Description: Received fresh labeled, "Thomas G. King, MR# 1213910,

periprostatic fat." It consists of multiple soft yellow-tan lobular

fibrofatty tissue fragments measuring 2.7 x 2.5 x 0.8 cm in aggregate. The

specimen is sectioned to reveal a soft yellow-tan lobular fibrofatty cut

surface. Entirely submitted in one block as 1A.

___________________________________________________________________

Source of Tissue: 2. Labeled #2, "right perivesical bundle margin"

Gross Description: Received fresh labeled, "Thomas G. King, MR# 1213910,

right perivesical

bundle margin." It consists of a soft red-brown

irregular tissue fragment measuring 0.2 x 0.1 x 0.1 cm. Entirely frozen in

one block as 2FS. The residual frozen section tissue is very tiny and may

not survive processing.

___________________________________________________________________

Source of Tissue: 3. Labeled #3, "prostate and seminal vesicles"

Gross Description: Received fresh labeled, "Thomas G. King, MR# 1213910,

prostate and seminal vesicles." It consists of a 21 gram, 3.0 x 2.5 x 2.5

cm red-tan hemorrhagic prostate with intact capsule, patent urethra, and

bilateral seminal vesicles and vasa deferentia. The right seminal vesicle

measures 3.2 x 1.5 x 0.7 cm, right vas 4.0 x 0.5 x 0.5 cm, left seminal

vesicle 3.0 x 1.0 x 0.5 cm, and left vas 4.5 0.5 x 0.5 cm. The right side

is inked black and the left side is inked blue and the specimen is

sectioned from apex to bladder neck to reveal tan-pink soft to firm

nodular cut surface. Sectioning of the bilateral semina

l vesicles and vasa

deferentia reveals tan fluid filled spaces. Representative sections are

submitted as designated for microscopic evaluation.

Designation of Sections: 3A- right apex, 3B- left apex, 3C- right base,

3D- left base, 3E- right anterior mid, 3F- right posterior mid, 3G-3H-

right posterior superior, 3I- left anterior mid, 3J- left posterior mid,

3K-3L- left posterior superior, M- right seminal vesicle and vas deferens,

3N- left seminal vesicle and vas deferens.

*Tumor and normal are given to Tumor Bank.

**90% of the specimen is submitted.

___________________________________________________________________

Source of Tissue: 4. Labeled #4, "right pelvic lymph nodes"

Gross Description: Received fresh labeled, "Thomas G. King, MR# 1213910,

right pelvic lymph nodes." It consists of a soft yellow-tan lobular

fibrofatty tissue fragment measuring 4.0 x 3.0 x 1.5 cm. The specimen is

sectioned to reveal three firm yellow-tan lymph nodes ranging from 0.3 cm

up to 1

.0 cm in diameter. The specimen is entirely submitted in 4A-4C.

Designation of Sections: 4A- one bisected lymph node, 4B- two small lymph

nodes, 4C- remaining fibrofatty tissue entirely submitted

___________________________________________________________________

Source of Tissue: 5. Labeled #5, "left pelvic lymph nodes"

Gross Description: Received fresh labeled, "Thomas G. King, MR# 1213910,

left pelvic lymph nodes." It consists of a soft yellow-tan lobular

fibrofatty tissue measuring 4.5 x 3.5 x 2.0 cm. The specimen is sectioned

to reveal multiple firm yellow-tan lymph nodes ranging from 0.5 cm up to

2.2 cm in diameter. The specimen is entirely submitted in 5A-5D.

Designation of Sections: 5A-5B- one large bisected lymph node in each

cassette, 5C- four small lymph nodes, 5D- remaining fibrofatty tissue

entirely submitted

RA/mm 3/30/21 2300

___________________________________________________________________

Intraoperative Diagnosis:

2FS: Fibrous tissue and

nerves, no tumor seen.

Intraoperative Pathologist: Douglas B. Flieder, MD

Pathology Fellow: Ashley Lentini, MD

Pathologist(s): Min Huang, MD, PhD

Electronically Signed By Min Huang, MD, PhD

Pathologist

4/1/2021 18:38

This case has been personally examined and interpreted by the attending

pathologist.

Written by
twostrats profile image
twostrats
To view profiles and participate in discussions please or .
Read more about...
7 Replies
Tall_Allen profile image
Tall_Allen

Why does it matter?

twostrats profile image
twostrats in reply toTall_Allen

I'm learning a lot in this forum. I'm assuming that eventually it might determine the course of action for my next treatment

tango65 profile image
tango65

The cancer is high risk, it is T3a. It has extended outside the prostate into the bladder.

twostrats profile image
twostrats in reply totango65

That's what I thought. My surgeon said he removed anything that went into the bladder during the RP thanks

Justfor_ profile image
Justfor_

A more sensitive PSA test will give you earlier warning in case of BCR. This is actionable, the rest is semantics.

LearnAll profile image
LearnAll

High or low risk can not be determined just by pathology report alone. You need a plethora of biomarkers and other data to ascertain risk level. If you just want to guess based on this detailed pathology report alone ..I would say you are in intermediate risk level category.

doc1947g profile image
doc1947g

"Prostatic adenocarcinoma, Gleason's score 7 (4+3) [Grade Group 3]. This means Intermediate advanced risk, like I was.

Not what you're looking for?

You may also like...

After RP who goes over Pathology?

We messaged Surgeon through portal and asked how many lymph nodes removed. He states that pathology...

Please Help Explain Results Please help explain Pathology report after Davinci Radical Prostatectomy w/ Extended Lymph Node Dissection 

Please help explain Pathology report after Davinci Radical Prostatectomy w/ Extended Lymph Node...

Strange case of my Dad's PCa

As many of you know, I have recently posted about my dad's Bone Mets PCa. Here's the strange part...
iLoveDad profile image

New member - requesting advice for next steps - rising PSA following radical prostatectomy - decipher test score considerations

See my radical prostatectomy details below. I am in the process of determining next steps for...